Evidence map›Paper›PMID 41280668›Full record

ArticleiScience2025

Impact of treatment history on drug resistance of metastatic colorectal cancer organoids.

Maarten A Huismans, Lidwien P Smabers, Sascha R Brunner, Arne van Hoeck, Demi van de Kaa, Ingrid A Franken, Emerens Wensink, Jan Koster, Richard Volckmann, Onno Kranenburg and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maarten A HuismansDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Lidwien P SmabersDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Sascha R BrunnerCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Arne van HoeckCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Demi van de KaaCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Ingrid A FrankenDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Emerens WensinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Jan KosterLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Richard VolckmannLaboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Onno KranenburgLaboratory of Translational Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Hugo J G SnippertCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Jeanine M L RoodhartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of metastatic colorectal cancer (mCRC) is impeded by drug resistance. We investigated how prior chemotherapy affects tumor genotype, phenotype, and resistance mechanisms by comparing 35 patient-derived metastatic organoids (PDOs) from pretreated and chemonaive patients with mCRC. Combining PDO drug sensitivity assessments with RNA and whole genome sequencing, we found PDOs from pretreated patients exhibited higher mutational load and more structural variants. Chemotherapy-related mutational signatures correlated with previous exposure. PDOs from oxaliplatin-resistant patients maintained this resistance, showing the upregulation of

Indexed as

Biological sciencesCancerHealth sciencesInternal medicineMedical specialtyMedicineOncology

Identifiers

PMID41280668
PMCPMC12636388

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.